Sei Investments Co. Acquires 46,132 Shares of Nurix Therapeutics, Inc. $NRIX

Sei Investments Co. grew its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 128.2% during the first quarter, Holdings Channel.com reports. The firm owned 82,108 shares of the company’s stock after acquiring an additional 46,132 shares during the quarter. Sei Investments Co.’s holdings in Nurix Therapeutics were worth $1,273,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. General Atlantic L.P. acquired a new position in Nurix Therapeutics during the fourth quarter worth $92,899,000. Morgan Stanley increased its stake in Nurix Therapeutics by 115.9% in the 4th quarter. Morgan Stanley now owns 4,881,069 shares of the company’s stock valued at $92,594,000 after buying an additional 2,620,323 shares during the last quarter. Rubric Capital Management LP bought a new stake in Nurix Therapeutics during the 4th quarter worth about $46,930,000. Braidwell LP bought a new stake in Nurix Therapeutics during the 4th quarter worth about $41,428,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Nurix Therapeutics by 195.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,248,361 shares of the company’s stock worth $61,622,000 after buying an additional 2,149,268 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on NRIX. Mizuho raised their price objective on Nurix Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Morgan Stanley increased their price target on Nurix Therapeutics from $36.00 to $38.00 and gave the company an “overweight” rating in a research report on Tuesday, July 28th. Royal Bank Of Canada raised their price target on Nurix Therapeutics from $33.00 to $36.00 and gave the company an “outperform” rating in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen raised shares of Nurix Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.21.

Insider Activity at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 5,394 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.00, for a total transaction of $107,880.00. Following the transaction, the insider owned 115,005 shares in the company, valued at approximately $2,300,100. This trade represents a 4.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 4,761 shares of Nurix Therapeutics stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total value of $115,977.96. Following the sale, the chief financial officer directly owned 40,166 shares of the company’s stock, valued at approximately $978,443.76. The trade was a 10.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,314 shares of company stock worth $589,361 in the last ninety days. 6.70% of the stock is owned by company insiders.

Nurix Therapeutics Stock Performance

Shares of NRIX opened at $25.96 on Wednesday. Nurix Therapeutics, Inc. has a 52 week low of $8.19 and a 52 week high of $26.36. The firm has a market cap of $2.69 billion, a P/E ratio of -7.52 and a beta of 1.79. The firm’s 50-day simple moving average is $21.62 and its 200 day simple moving average is $18.15.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.08). Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%.The company had revenue of $9.04 million for the quarter, compared to analyst estimates of $15.29 million. As a group, equities analysts forecast that Nurix Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.